Victoria Mainardi

Victoria Mainardi

Auto-generated profile, based on publicly available information

Victoria Mainardi

Hospital Central de Las Fuerzas Armadas

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2020 in REVISTA MEDICA DEL URUGUAY
Verified
Journal Article
Open access
VMVictoria Mainardi
Victoria Mainardi
JMJosemaría Menéndez
Josemaría Menéndez
MVMarcelo Valverde
Marcelo Valverde
GMGonzalo San Martín
Gonzalo San Martín
JHJimena Hurtado
Jimena Hurtado
SGSolange Gerona
Solange Gerona

20 February 2023 in Medical Clinics of North America
Verified
Journal Article
Closed access
LDLuis Antonio Díaz
Luis Antonio Díaz
JPJosefina Pages
Josefina Pages
VMVictoria Mainardi
Victoria Mainardi
MMManuel Mendizabal
Manuel Mendizabal

2 July 2025 in Annals of Hepatology
Verified
Journal Article
Open access
VMVictoria Mainardi
Victoria Mainardi
JPJosefina Pages
Josefina Pages
JMJosemaría Menendez
Josemaría Menendez
RZRodrigo Zapata
Rodrigo Zapata
LDLuis Antonio Díaz
Luis Antonio Díaz
AVAlejandra Villamil
Alejandra Villamil
Liver transplantation (LT) is the standard of care therapy for patients with decompensated cirrhosis, early-stage hepatocellular carcinoma, acute liver failure, and other expanding indications. Latin America is a highly heterogeneous region characterized by an uneven distribution of socio-economic conditions and irregular access to health resources, and consequently LT activity varies across it. This current guidance of preoperative care in LT represents a collaborative effort to assess and standardize preoperative evaluation of liver transplant candidates in Latin America. It is the first position paper of the special interest group on LT of the Latin American Association for the Study of the Liver (ALEH), which draws evidence-based comprehensive recommendations regarding who to refer, the LT assessment and how to manage the patient on the waiting list, taking into consideration their applicability in Latin America.

1 February 2026 in Sage Open Chronic Disease
Verified
Journal Article
Open access
VMVictoria Mainardi
Victoria Mainardi
HZHuaiyang Zhong
Huaiyang Zhong
AAAlec Aaron
Alec Aaron
DODaniela Olivari
Daniela Olivari
SGSolange Gerona
Solange Gerona
JCJagpreet Chhatwal
Jagpreet Chhatwal
Background: The World Health Organization (WHO) targets hepatitis C virus (HCV) elimination by 2030. Despite universal access to direct-acting antivirals, Uruguay has faced gaps in HCV diagnosis and linkage-to-care. Objective: To estimate HCV burden and evaluate the epidemiological and economic impact of alternative testing and treatment strategies in Uruguay, including those required to achieve WHO elimination targets. Design: Decision-analytic modeling study using the Hep C Elimination Tool, an individual-level state-transition microsimulation model. Methods: We conducted a national HCV disease burden assessment, including viremic prevalence, incidence, liver-related morbidity, mortality, and cascade-of-care indicators, using multiple data sources. The calibrated model simulated two scenarios Status Quo, reflecting current screening and treatment levels (5% and 70%), and Elimination, defined by testing and treatment scale-up required to achieve WHO targets (90% diagnosis, 80% treatment, and 80% incidence reduction). Two follow-up rate assumptions (reflecting progression from antibody positivity to RNA confirmation and treatment initiation) were applied: current (based on observed national data) and maximized (assuming complete progression from diagnosis to treatment). Outcomes included projected HCV prevalence, incidence, liver-related mortality, diagnosis and treatment coverage by 2030, and cumulative healthcare costs through 2050. Results: In 2022, an estimated 19,559 individuals were living with chronic HCV infection in Uruguay. Under Status Quo scenario with current follow-up, diagnosis and treatment coverage would reach 23% and 17% by 2030, with limited incidence reduction (−13%) and largely unchanged liver-related mortality. In contrast, elimination-aligned strategies with expanded screening (15 to 30%) and treatment uptake (70 to 80%), with maximized follow-up, achieved up to 91% diagnosis and treatment coverage, 89% incidence reduction, and 56% liver-related mortality reduction by 2030. Cumulative undiscounted expenditures were reduced by up to 43.5% versus Status Quo, with savings attenuated but preserved after discounting. Conclusion: Model projections suggest that HCV elimination in Uruguay may be feasible and cost-saving under scenarios that substantially expand testing and improve linkage to care. These findings highlight the potential value of scaling up diagnostic and treatment to reduce HCV burden and inform national planning efforts.

1 September 2019 in Acta Biológica Colombiana
Verified
Journal Article
Open access
PDF file
DQDiana Carolina Quintero
Diana Carolina Quintero
Santiago MirazoSantiago Mirazo
Santiago Mirazo
JPJaime Parra-Suescún
Jaime Parra-Suescún
ALAlbeiro López-Herrera
Albeiro López-Herrera
VMVictoria Mainardi
Victoria Mainardi
SOSergio Orduz
Sergio Orduz
Hepatitis E virus (HEV) is considered one of the leading causes of acute viral hepatitis worldwide, and about 20 million infections and approximately 57 000 deaths occurred every year. However, little is known about the replicative virus cycle due to the absence of a consensus cell culture model. A549 cell line is considered susceptible to HEV genotype 3, however, both viral strain and cell culture conditions could affect the viral isolation in vitro. The objective of this work was to isolate in vitro an HEV-3 strain obtained from human feces. To this, a genotype 3 HEV strain previously identified by genetic characterization was inoculated in A549 monolayers, and incubated for two hours at 37 °C. Five days post-infection, cells were passaged (subcultured) for the first time, and serial passages were done on average every four days during 41 days. HEV replication was evaluated through RT-qPCR in each passage, and reinfection of the cell line with the viral progeny derived from A549 infected monolayers was assessed through immunofluorescence and RT-qPCR. Viral RNA was detected in each passage from infected monolayers, and the highest amount was found after 26 days (2 x 106 copies/μL). In reinfection assay, capsid antigen was detected perinuclearly and forming foci, and 1x104 copies/μL of viral RNA was detected after 96 hours post infection. This shows that HEV recovered from the cell lysate monolayers was infectious. This viral isolate offers a critical tool to study the unknown aspect of HEV infection.

1 September 2021 in Annals of Hepatology
Verified
Journal Article
Open access
JOJuan Otegui
Juan Otegui
VMVictoria Mainardi
Victoria Mainardi
DODaniela Olivari
Daniela Olivari
AFAna Maria Fernandez
Ana Maria Fernandez
Carolina de de Aguiar FerreiraCarolina de de Aguiar Ferreira
Carolina de de Aguiar Ferreira
SGSolange Gerona
Solange Gerona